Drug Profile
Research programme: EML4-ALK modulators - Astellas/Cell Signaling Technology
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma; Cell Signaling Technology
- Class Diagnostic agents
- Mechanism of Action Anaplastic lymphoma kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer(Diagnosis) in USA
- 07 Jan 2013 Preclinical trials in Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
- 24 Feb 2011 Investigation in Non-small cell lung cancer in USA (unspecified route)